Morgan Stanley analyst Mark Purcell initiated coverage of Roche with an Underweight rating and $38 price target. The analyst added six American depository receipts to the firm’s European Union Pharmaceuticals coverage. The stock’s fundamental views are fully aligned with those the firm has on the underlying stocks, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RHHBY:
- GLP-1 Anti-Obesity Drugs: Slim Waistlines, Fat Profits
- Roche assumed with a Neutral at UBS
- Halozyme announces Roche receives EC marketing authorization of Tecentriq SC
- Roche downgraded to Underweight from Equal Weight at Morgan Stanley
- European Commission approves Roche’s Tecentriq SC, the EU’s first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types
